• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Arena Pharmaceuticals

Arena Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report 2017: Focus on Endothelin Receptor Antagonist, Prostacyclin and Prostacyclin, PDE-5 Inhibitors & sGC Stimulator - ...

    Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report 2017: Focus on Endothelin Receptor Antagonist, Prostacyclin and Prostacyclin, PDE-5 Inhibitors & sGC Stimulator - Research and Markets

  2. Global Equities: What’s Up With Emerging Markets?

    Arena Pharmaceuticals' future depends on its late-stage obesity drug.

©2017 Morningstar Advisor. All right reserved.